Compare drug alternatives

Rybelsus ® Alternatives

Rybelsus ®(semaglutide)
Trijardy XR®(metformin hydrochloride)
Prescription Only
Rybelsus tablets (semaglutide) are used by adults with type 2 diabetes to manage blood sugar levels. Taken once daily, Rybelsus is combined with diet and exercise. It boosts...
Prescription Only
Trijardy XR tablets combine empagliflozin, linagliptin, and metformin, which are all oral medications for managing blood sugar levels. This prescription medication, Trijardy XR,...
Dosage & Administration
Oral. Learn more.
Oral . Learn more.
Start RYBELSUS® with 3 mg once daily for 30 days. The 3 mg dosage is intended for treatment initiation. •After 30 days on the 3 mg dosage, increase the dosage to 7 mg once daily. •The dosage may be increased to 14 mg.. Learn more.
The maximum recommended dose of TRIJARDY XR is 25 mg empagliflozin, 5 mg linagliptin and 2000 mg metformin HCl. Take once daily with a meal in the morning. Swallow whole; do not split, crush, dissolve, or chew.. Learn more.
Latin Shorthand
Initiate RYBELSUS® at 3 mg qd for 30 days. Then, escalate to 7 mg qd after 30 days. Consider up-titrating to 14 mg qd.. Learn more.
Max dose TRIJARDY XR: 25 mg empagliflozin, 5 mg linagliptin, 2000 mg metformin HCl. Take 1x daily with AM meal. Swallow whole; no splitting, crushing, dissolving, or chewing.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
$150 for a 1-month supply; $300 for a 2-month supply; $450 for a 3-month supply. Learn more.
$175 per month. Learn more.
Assistance Expiration
24 months. Learn more.
12/31/23. Learn more.
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
Most common adverse reactions (incidence ≥5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.. Learn more.
Most common adverse reactions (5% or greater incidence) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, and gastroenteritis. . Learn more.
Mechanism of Actions (MoA)
GLP-1 Receptor Agonists. Learn more.
SGLT2 Inhibitors. Learn more.
Special Populations
What is the risk of using RYBELSUS® during pregnancy?

The available data with RYBELSUS® use in pregnant women are insufficient to evaluate the drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Clinical considerations should be noted regarding the risks of poorly controlled diabetes during pregnancy.

How should RYBELSUS® be used during pregnancy?

RYBELSUS® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

What animal reproduction studies have been conducted with RYBELSUS®?

In pregnant rats, embryofetal mortality, structural abnormalities, and alterations to growth occurred at maternal exposures below the maximum recommended human dose (MRHD) based on AUC. Similar findings were observed in rabbits and cynomolgus monkeys at exposures below the MRHD.

What is the estimated background risk of major birth defects and miscarriage?

The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c >7, and has been reported to be as high as 20–25% in women with a HbA1c >10. In the general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

What are the clinical considerations for poorly controlled diabetes during pregnancy?

Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. It also increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Is there any information on RYBELSUS® use during lactation?

There are no data on the presence of semaglutide (active ingredient in RYBELSUS®) in human milk, its effects on the breastfed infant, or milk production. Semaglutide was detected in the milk of lactating rats. Due to species-specific differences, the clinical relevance of these data is not clear.

What should be considered regarding lactation and RYBELSUS®?

Breastfeeding is not recommended during treatment with RYBELSUS® due to potential accumulation of certain substances (such as SNAC) in breast milk. There are alternative formulations of semaglutide that can be used during lactation.

When should RYBELSUS® be discontinued in relation to a planned pregnancy?

RYBELSUS® should be discontinued in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.

Is RYBELSUS® safe for pediatric use?

The safety and effectiveness of RYBELSUS® have not been established in pediatric patients (younger than 18 years).

How is RYBELSUS® affected by renal impairment?

The safety and effectiveness of RYBELSUS® was evaluated in patients with moderate renal impairment, showing no clinically relevant change in semaglutide pharmacokinetics. No dose adjustment of RYBELSUS® is recommended for patients with renal impairment.

How is RYBELSUS® affected by hepatic impairment?

In subjects with different degrees of hepatic impairment, no clinically relevant change in semaglutide pharmacokinetics was observed. No dose adjustment of RYBELSUS® is recommended for patients with hepatic impairment.